Tanvex received marketing authorization from Health Canada

Tanvex received marketing authorization from Health Canada Oct. 17, 2021 Tanvex BioPharma, Inc. (TWSE: 6541) announced that Health Canada had completed their review of our submission of NYPOZI (TX01) and granted marketing authorization. This milestone achievement positions the company a step closer to product commercialization in Canada. NYPOZI (TX01), a proposed biosimilar to the reference product – Amgen’s NEUPOGEN® -- is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. According to data from IQVIA, filgrastim product sales were close to $100 million (CAD) in the Canada for the 12 months ended June, 2021. About Tanvex Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.

The release as fetched from its publisher. tanvex.com ↗